title: [Assessment of the treatment with imiquimod in persistent infection by human papillomavirus with the polimerase chain reaction method].
abstract: BACKGROUND
  Molecular studies have shown that oncogenic genotypes of human papillomavirus (HPV) are the main risk factor for cervical cancer development. Sub-clinical wound does not cause symptoms and is diagnosed by colposcopy or histology, in addition the latent infection is associated with the presence of DNA of the HPV, but when clinical and histological abnormalities are not presented only molecular techniques can detect this infection.
  
  
  OBJECTIVE
  To determine if complementary processing with imiquimod, recent medicament with powerful antiviral activity in vitro as in vivo, reduces the cervical persistence of HPV.
  
  
  METHODS
  This study was carried out with 87 patients, who had antecedents of HPV cervical and intraepithelial wound with low degree. Patients were divided as follows: treated with cryotherapy, cervical loop electrosurgical and imiquimod, all with diagnosis by cervical cytology, colposcopy and polymerase chain reaction (PCR) for HPV. At 3, 6 and 12 months after the processing, PCR, cervical cytology and colposcopy control were carried out again.
  
  
  RESULTS
  Out of the 87 patients studied, 11% (10) patients treated with cervical cytology were positive for VPH; with colposcopy 8% (7) of patients and with PCR 40% (34) of patients; decreased persistence with combined methods of loop and imiquimod was obtained in 29% (5) patients; however, when utilized imiquimod alone, there were 55% (11) patients with persistence determined by PCR method.
  
  
  CONCLUSIONS
  Imiquimod appears to be beneficial in 45% of the patients, in contrast with efficacy reported until 85% in genitals and annals warts, in addition, the capacity of eliminating the viruses has been shown, therefore it is possible that its potential effect could be observed long-time. It is evident that the percentages of viral detection are improved for PCR method, compared with indirect methods as cervical cytology and colposcopy, which is favorable when virus serotypes are of high degree of transformation and ablative methods should be conservatives due to fertility motives.
authors.affiliation: Unidad de Investigación Médica en Enfermedades Endocrinas del Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, DF México.
authors.forename: Tomás
authors.initials: T
authors.lastname: Hernández Quijano
authors.forename: Berenice
authors.initials: B
authors.lastname: Illanes Aguiar
authors.forename: Natividad
authors.initials: N
authors.lastname: Salas Linares
authors.forename: Luz del Carmen
authors.initials: Ldel C
authors.lastname: Alarcón Romero
authors.forename: Marcelino
authors.initials: M
authors.lastname: Hernández Valencia
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000634:Aminoquinolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077271:Imiquimod; D027383:Papillomaviridae / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000188:drug therapy* / Q000628:therapy / Q000821:virology; D016133:Polymerase Chain Reaction; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
chemical_list: D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000077271:Imiquimod